New psychedelic-like drugs could treat depression without making you trip
UC Davis researchers created brand-new psychedelic-like compounds by shining UV light on amino acid-based molecules. These compounds activated key serotonin receptors tied to brain plasticity and mental health benefits, but surprisingly did not cause hallucination-like behavior in animal tests. Scientists say the discovery could lead to future treatments for depression, PTSD, and addiction without the intense psychedelic experience.
External link. We are not responsible for the content.
Read more ↗More From ScienceDaily Psychedelics
Scientists say just 7 days of meditation can rewire your brain
An intensive seven-day meditation retreat triggered striking changes across the brain and body, including shifts tied...
Magic mushrooms may reshape the brain long after the trip ends
A single dose of psilocybin produced measurable changes in brain activity and possible changes in brain structure tha...
Is cannabis safe after 65? Stanford experts reveal 5 risks older adults should know
Cannabis use among older adults is rising fast, but today’s marijuana is far more potent than many people realize — a...
Latest News
Psychedelic Medicine Is Having an Identity Crisis — And That’s a Good Thing
For most of the last decade, the story of psychedelic medicine was a story about the trip itself. Guided sessions. Ey...
Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High
Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the...
Weekly Psychedelic Policy Briefing – August 9, 2026
Jack Gorsline, investigative journalist, covers four federal developments this week. The Department of Veterans Affai...
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an A...
Why don’t some people respond to psychedelics? 5 Questions for psychologist Rachel Ham
Ham discusses doing interviews with clinical trial participants who didn’t experience substantial benefits.
Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?
MAPS co-executive director Ismail Lourido Ali on what the April 2026 executive order, the Texas and Colorado funding ...